Navigation Links
Labopharm to host webcast presentation on novel trazodone formulation for treatment of major depressive disorder
Date:11/24/2008

esearcher and teacher in psychiatry with subspecialty expertise in psychopharmacology. Dr. Stahl has edited three books, and written four others, including the best-selling textbook, Essential Psychopharmacology, now in its third edition and the best-selling clinical manual, Essential Psychopharmacology Prescriber's Guide.

Dr. Sheehan has been a consultant to the World Health Organization, the World Federation of Societies of Biological Psychiatry, the International Academy for Biomedical and Drug Research, the US Food and Drug Administration, and a research grant reviewer for the National Institute for Mental Health (NIMH). Dr. Sheehan has been invited to give over 1600 lectures in 64 countries throughout the world on anxiety and mood disorders, psychopharmacology and biological psychiatry. He was elected as a member of the American College of Psychiatrists and is a Distinguished Fellow of the American Psychiatric Association.

    About Labopharm's Novel Trazodone Formulation and the Market for
    Antidepressants

One-half of patients being treated with antidepressants discontinue therapy within a year for reasons related to efficacy and/or tolerability, including delayed onset of therapeutic response, insomnia or sleep disturbance, agitation, exacerbation of anxiety, sexual dysfunction, weight gain and somnolence. Labopharm has developed a novel once-daily formulation of 150 mg and 300 mg of trazodone hydrochloride, a serotonin antagonist reuptake inhibitor (SARI), for the treatment of major depressive disorder (MDD) to address patient needs in the current depression landscape, providing an effective and convenient treatment option. In a Phase III placebo controlled study of patients with MDD, Labopharm's novel trazodone formulation demonstrated antidepressant efficacy, including rapid onset of therapeutic response, improved overall quality of sleep, a well tolerated adverse event profile, a very low rat
'/>"/>

SOURCE Labopharm Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine news :

1. Labopharm To Present Poster On Onset Of Analgesic Effect Of Once-Daily Tramadol At Congress Of The European Society Of Regional Anaesthesia And Pain Therapy
2. Labopharm provides update on U.S. regulatory process for once-daily Tramadol
3. Labopharm completes enrolment for Phase III clinical study for its once-daily trazodone antidepressant drug
4. Labopharm appeals FDAs decision on once-daily tramadol
5. Labopharm to host conference call Friday, November 9, 2007 at 8:30 a.m. (ET)
6. Labopharm to present at CIBC World Markets 18th Annual Healthcare Conference
7. Labopharm Reports Results for Third Quarter Fiscal 2007
8. Labopharm receives FDA response to appeal of Approvable Letter for once-daily tramadol
9. Labopharm enters into licensing and distribution agreement for once-daily tramadol in Australia with iNova
10. Canadian Marketing and Sales Effort for Labopharms Once-Daily Tramadol Product to Expand Significantly
11. Labopharm Reports Positive Results for Phase III Study on Once-daily Trazodone
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/4/2015)... York, New York (PRWEB) March 04, 2015 ... was reviewing the cardiovascular risks potentially associated with low ... Drug Administration (FDA) announced that it will now require ... may increase their risk for heart attacks and strokes. ... 3, 2015, the agency also stated that it was ...
(Date:3/4/2015)... " Optrix by Body Glove ” ... Tech Report, which takes a look at the latest ... Scott Steinberg, a special reporter for NewsWatch and a ... viewers how they have an ultra-rugged, waterproof case with ... a major player at the Consumer Electronics Show in ...
(Date:3/4/2015)... (PRWEB) March 04, 2015 The popular ... of their new L-Style Revolution™ Program. The customized program ... and women of all health and fitness levels to ... goals faster than traditional methods. , “We’re really proud ... customized plans based on award winning techniques to help ...
(Date:3/4/2015)... 2015 Information Innovators Inc . ... has joined the company as Chief Technology Officer. ... focus for the company, including customer-centric strategies and initiatives, ... years of experience as a technology executive and visionary. ... at the FBI including oversight of enterprise data management, ...
(Date:3/4/2015)... In a small ceremony with 20 attendees and ... facility in New Port Richey on February 24, 2015 with ... allow the Florida drug detox facility to continue ... through treatment and education. “Due to our unique medical-detox process ... States, we made the decision that expanding our facility was ...
Breaking Medicine News(10 mins):Health News:Testosterone Lawsuit Attorneys at Bernstein Liebhard LLP Comment on FDA Mandate For New Cardiovascular Warnings on Low T Therapy Drugs 2Health News:Testosterone Lawsuit Attorneys at Bernstein Liebhard LLP Comment on FDA Mandate For New Cardiovascular Warnings on Low T Therapy Drugs 3Health News:Testosterone Lawsuit Attorneys at Bernstein Liebhard LLP Comment on FDA Mandate For New Cardiovascular Warnings on Low T Therapy Drugs 4Health News:A Waterproof Phone Case with an Interchangeable Lens System was Featured on NewsWatch Television on January 30, 2015 2Health News:The Makers of Liporidex, The Popular Sports Nutrition Supplement Brand, Launches Its New L-Style Revolution™ Diet & Exercise Program That Promises Turbo Charged Results 2Health News:Information Innovators Inc. Announces Mr. John Dvorak as the New Chief Technology Officer 2Health News:Information Innovators Inc. Announces Mr. John Dvorak as the New Chief Technology Officer 3Health News:Novus Medical Detox Hosts Ribbon Cutting Ceremony at Pasco County Facility 2Health News:Novus Medical Detox Hosts Ribbon Cutting Ceremony at Pasco County Facility 3
... has been published in the World Journal of Gastroenterology ... was the first case of gastric carcinosarcoma obtained in ... admitted by Dr. Tomislav Randjelovic as surgeon and Dr. ... Dr. Randjelovic and his team; the anatomical and patoanatomical ...
... Nov. 14 MediNotes Corporation, a,leading provider of ... medical practices, today announced that MediNotes e reached,another ... Systems (PMS), using HL7 as the industry standard ... represents a 15%,increase in the amount of PMS ...
... launched at MEDICA in Germany, NEW YORK, Nov. ... leading developer of biosensor and microprocessor,technologies for use in ... PulseOx 6100(TM), two new oximetry devices, will,be formally introduced ... for,Medicine in Dusseldorf, Germany between 14th - 17th November, ...
... Tenn., Nov. 14 AT&T Inc. (NYSE: ... managed services to Howell Allen,Clinic, a six-location, neurosurgical ... serves patients in Nashville, middle,Tennessee, southern Kentucky and ... three-year contract, AT&T will deliver a robust,Managed Internet ...
... Region 5 has awarded a $40,000 grant to the ... improve conditions for,asthma sufferers., Specifically, the mission of ... emergency room visits, missed school and work days, and,deaths ... health and welfare of children and adults,who suffer from ...
... Innovative ... INDIANAPOLIS, Nov. 14 Anthem Blue Cross and Blue Shield,in ... that,incorporates public health data to identify and help address major ... to collaborate,with local and state officials, as well as community ...
Cached Medicine News:Health News:MediNotes EMR Now Interfaces With 76 Practice Management Systems, Allowing More Medical Practices to Replace Their Patients' Aging Paper Medical Records 2Health News:SPO Medical Unveils New Oximetry Devices for European Markets 2Health News:SPO Medical Unveils New Oximetry Devices for European Markets 3Health News:Howell Allen Clinic Selects AT&T for New Network Services 2Health News:Howell Allen Clinic Selects AT&T for New Network Services 3Health News:Anthem Blue Cross and Blue Shield in Indiana Releases State Health Index 2Health News:Anthem Blue Cross and Blue Shield in Indiana Releases State Health Index 3Health News:Anthem Blue Cross and Blue Shield in Indiana Releases State Health Index 4
(Date:3/4/2015)... 2015 Alimera Sciences, Inc. (NASDAQ: ... specializes in the research, development and commercialization of ... the fourth quarter and year ended December 31, ... pivotal year for Alimera Sciences, most notably having ... for the treatment of diabetic macular edema," said ...
(Date:3/4/2015)... HEIGHTS, Mich. , March 4, 2015 ... provider of infusion pumps and related services for the ... fourth quarter and full year 2014 financial results on ... The Company will also conduct a conference call ... p.m. Eastern Time to discuss fourth quarter and full ...
(Date:3/4/2015)... , March 4, 2015 XBiotech announced ... study in patients with moderate to severe plaque ... open-label Phase II trial evaluated the potential benefit ... that targets interleukin-1 alpha (IL-1a). IL-1a is a ... present in skin lesions. The Company claims that ...
Breaking Medicine Technology:Alimera Sciences Reports Fourth Quarter and Full Year 2014 Financial Results 2Alimera Sciences Reports Fourth Quarter and Full Year 2014 Financial Results 3Alimera Sciences Reports Fourth Quarter and Full Year 2014 Financial Results 4Alimera Sciences Reports Fourth Quarter and Full Year 2014 Financial Results 5Alimera Sciences Reports Fourth Quarter and Full Year 2014 Financial Results 6Alimera Sciences Reports Fourth Quarter and Full Year 2014 Financial Results 7Alimera Sciences Reports Fourth Quarter and Full Year 2014 Financial Results 8Alimera Sciences Reports Fourth Quarter and Full Year 2014 Financial Results 9Alimera Sciences Reports Fourth Quarter and Full Year 2014 Financial Results 10Alimera Sciences Reports Fourth Quarter and Full Year 2014 Financial Results 11Alimera Sciences Reports Fourth Quarter and Full Year 2014 Financial Results 12Alimera Sciences Reports Fourth Quarter and Full Year 2014 Financial Results 13Alimera Sciences Reports Fourth Quarter and Full Year 2014 Financial Results 14XBiotech Announces Phase II Psoriasis Study Results in JAMA Dermatology 2
... (bDNA) delivers unmatched precision and reproducibility, so you ... viral load values they can trust.,you detect significant ... critical decision points - without the variability seen ... to choose VERSANT HIV bDNA, consider this: it's ...
... an FDA-approved HIV-1 RNA assay, is utilized for ... the regulatory approval for HIV-1 therapies, and is ... laboratories worldwide. , The AMPLICOR HIV-1 ... acid amplification test for the quantification of Human ...
... a single use rapid test, for the detection ... whole blood (venipuncture). Uni-Gold Recombigen HIV is intended ... an aid in diagnosis of infection with HIV-1. ... multi-test algorithms designed for the statistical validation of ...
The Becton™ Colles Fracture Plate has proven clinical outcomes and has excellent patient acceptance compared to external fixation. It provides a cost effective treatment option through a simple...
Medicine Products: